Abstract: An isolated nucleic acid molecule which hybridizes under stringent conditions with the nucleic acid shown in SEQ ID NO:32 or its complement or the nucleic acid shown in SEQ ID NO:34 or its complement, and which encodes mitogen activated protein kinase kinase protein.
Type:
Grant
Filed:
April 18, 1995
Date of Patent:
September 2, 1997
Assignee:
The Board of Regents of the University of Washington
Inventors:
Rony Seger, Dalia Seger, Natalie G. Ahn, Edwin G. Krebs
Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
September 2, 1997
Assignee:
Sloan-Kettering Institute
Inventors:
Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsmann, Malcolm A. S. Moore
Abstract: The present invention provides blood substitutes comprised of recombinantly produced mutant hemoglobin having an osmolarity greater than 303 milliosmoles per liter and less than 800 milliosmoles per liter. Such hyperosmolar blood substitute additionally comprises a physiologically acceptable molecule less diffusible than dextrose.
Abstract: The invention pertains to the field of thrombin inhibitors and describes the production of modified desulphatohirudins, particularly desulphatohirudins, with the aid of genetic engineering. The present invention is also directed to a method for the denaturation and renaturation of a modified desulphatohirudin to a biologically active thrombin inhibitor and the combination of two or more of desulphatohirudins to form higher molecular weight thrombin inhibitors.
Type:
Grant
Filed:
March 29, 1995
Date of Patent:
August 26, 1997
Assignee:
Ciba-Geigy Corporation
Inventors:
Hugo Grossenbacher, Jui Yoa Chang, Walter Marki
Abstract: The present invention relates to methods for the induction of tendon/ligament-like tissue formation, wound healing and ligament and other tissue repair, using a composition comprising BMP-12, BMP-13 or MP-52, or combinations of the above.
Type:
Grant
Filed:
December 22, 1994
Date of Patent:
August 19, 1997
Assignees:
Genetics Institute, Inc., President and Fellows of Harvard College
Inventors:
Anthony J. Celeste, John M. Wozney, Vicki A. Rosen, Neil M. Wolfman, Gerald H. Thomsen, Douglas A. Melton
Abstract: An antigenic preparation is provided which contains a 31 Kd outer membrane protein from Leptospira which can be used immunologically as a vaccine for leptospirosis caused by this organism.
Type:
Grant
Filed:
December 20, 1994
Date of Patent:
August 19, 1997
Assignee:
The Regents of the University of California
Inventors:
David A. Haake, David R. Blanco, Cheryl I. Champion, Michael A. Lovett, James N. Miller
Abstract: Mammalian proteins and muteins thereof, designated interleukin-4s (IL-4s), are provided which exhibit both B cell growth factor activity and T cell growth factor activity. Compounds of the invention include native human and murine IL-4s, muteins thereof, and nucleic acids which are effectively homologous to disclosed cDNAs, and/or which are capable of coding for mammalian IL-4s and their muteins.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
August 12, 1997
Assignee:
Schering Corporation
Inventors:
Frank Lee, Takashi Yokota, Ken-ichi Arai, Timothy Mosmann, Donna Rennick
Abstract: A composition for the promotion of cell proliferation and tissue repair in animals having as active ingredients a TGF-.beta. which is activated by either a TGF-.alpha. or an EGF or both; and methods for administration. As another embodiment these active ingredients can be admixed with other (secondary) growth factors.
Type:
Grant
Filed:
April 16, 1993
Date of Patent:
August 12, 1997
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Abstract: A method for bacterially producing IGF-I is disclosed in which Gram-negative bacteria are caused to express a gene consisting of a lamB or ompF signal sequence operatively joined to a DNA sequence encoding IGF-I and producing IGF-I which is secreted into the periplasmic space of the bacteria.
Abstract: The present invention relates to variants of hirudin containing an amino acid different from the amino acid in the natural form at position 47 or 63.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
July 22, 1997
Assignee:
Transgene S.A.
Inventors:
Michael Courtney, Eric DeGryse, Gerard Loison, Yves LeMoine
Abstract: Disclosed is an improved process for obtaining purified, monomeric, intact, correctly-folded insulin-like growth factor-I (also known as somatomedin-C). The improvements, consisting primarily of the addition of an IGF-I unfolding/refolding step and the substitution of a reverse phase chromatography step for a gel filtration chromatography step result in a three-fold increase in final yield. The process includes the following steps, in order: first cation exchange, unfolding/refolding, hydrophobic interaction chromatography, second cation exchange, and reverse phase chromatography.
Type:
Grant
Filed:
April 14, 1995
Date of Patent:
July 22, 1997
Assignee:
Cephalon, Inc.
Inventors:
Russell A. Brierley, Joan N. Abrams, John M. Hanson, Francis C. Maslanka
Abstract: Cycloolefin block copolymers, which in particular are suitable as phase promoters, are preferably obtained by copolymerization of polycyclic olefins, such as norbornene, with acyclic olefins, such as ethylene, by, at a molecular weight distribution M.sub.w /M.sub.n of the polymer block forming of less than 2, changing the reaction conditions one or more times in such a way that the monomer/comonomer ratio changes by at least 10% or a further polymerizable monomer is metered into the monomer or the monomers.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
July 8, 1997
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Michael-Joachim Brekner, Frank Osan, Jurgen Rohrmann
Abstract: A method of measuring and assessing T and B cell immunokinetics in human, particularly cancer immunokinetics by applying the multiple regression analysis, one of multivariate data analyses, to the counts in blood samples of CD3, CD4, CD8 and OKIa1 positive lymphocytes, helper, suppression inducer, cytotoxic and suppressor T lymphocytes, activated suppression inducer/helper and activated suppressor/cytotoxic T lymphocytes and natural killer cell, monocyte, basophil, eosinophil and neutrophil.
Abstract: A method of increasing the yield and heme saturation of hemoproteins in microorganisms. In this method, an effective amount of a heme precursor is added to a culture of hemoprotein producing microorganisms.
Abstract: Adhesive beads comprise a core comprising a pressure sensitive adhesive material and an essentially discontinuous organic polymer disposed about the core. The beads are free-flowing at room temperature. Upon application of heat and/or pressure the core is activated and blends with the coating to provide a pressure sensitive adhesive.
Type:
Grant
Filed:
January 24, 1996
Date of Patent:
April 29, 1997
Assignee:
Minnesota Mining and Manufacturing Company
Inventors:
Joseph P. Callahan, Jr., Rudyard M. Enanoza, Mark D. Weigel
Abstract: Polymeric glass modifier having a partially crosslinked structure capable of effectively reducing the surface gloss of a thermoplastic resin, is prepared by (a) emulsion polymerizing an acrylic monomer, an ethylenically unsaturated cyanide compound end, optionally, an aromatic vinyl monomer to obtain a copolymer latex of a linear structure; (b) conducting a crosslinking emulsion polymerization of the resultant linear copolymer latex obtained in step (a) with an addition of the same monomers used in step (a), an acrylamide inter-particle crosslinking agent and an ethylenically unsaturated crosslinking agent to produce a partially crosslinked latex; and (c) coagulating and interparticle crosslinking the partially crosslinked latex obtained in step (b) with an addition of an acid to obtain the polymeric gloss modifier.
Type:
Grant
Filed:
April 21, 1994
Date of Patent:
March 18, 1997
Assignee:
Lucky Limited
Inventors:
Jin N. Yoo, Dong O. Kim, Yeong R. Chang, Jong K. Yeo
Abstract: Polar thermoplastic polyolefin blends are provided which are flexible and are particularly useful in replacing polyvinyl-chloride sheeting used as liners, folders, etc. The blends comprise, in general, a non-polar thermoplastic polyolefin, a polar ethylene copolymer, and an acid grafted olefin polymer as a compatibilizing agent, all of which are chlorine-free.
Abstract: Method to produce bowls of a plastic material, whereby polypropylene is mixed with an additive and/or dye after suitable dosing and is introduced into a moulding press, wherein it is heated to 180.degree.-210.degree. C., and is then injected into a mould, where it is kept under a further pressure for 20-60 seconds, the product then being extracted and cooled in water before removal of flash so as to produce the bowl. Bowl consisting of polypropylene and produced according to the above method.
Type:
Grant
Filed:
September 13, 1995
Date of Patent:
February 11, 1997
Assignee:
Plastic Legno Giocattoli di Contessi & C.Snc
Abstract: A polyolefin molding composition essentially comprising a polyolefin derived from an olefin having at least 3 carbon atoms, of the formula R.sup.a --CH.dbd.CH--R.sup.b, in which R.sup.a and R.sup.b are identical or different and are hydrogen or C.sub.1 -C.sub.15 -alkyl, straight-chain or branched, or R.sup.a and R.sup.b, together with the atoms connecting them, form a ring, where the polyolefin molding composition may contain up to 10% by weight of ethylene or a second olefin as defined above as comonomer, having a molecular weight M.sub.w of >80,000 g/mol, a polydispersity M.sub.w /M.sub.n of from 1.8 to 3.5, a viscosity of >70 cm.sup.3 /g, a melting point of from 130.degree. to 160.degree. C., an aligned transparency of >30% and an ether-extractable content of less than 2% by weight.
Type:
Grant
Filed:
March 20, 1996
Date of Patent:
January 28, 1997
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Andreas Winter, Horst Bormuth, Bernd Bachmann